title: Association of XRCC3 Thr241Met polymorphisms and gliomas risk: evidence from a meta-analysis.
abstract: The relationship between the X-ray repair cross-complementing group 3 (XRCC3) Thr241Met polymorphism and gliomas remains inclusive or controversial. For better understanding of the effect of XRCC3 Thr241Met polymorphism on glioma risk, a meta-analysis was performed. All eligible studies were identified through a search of PubMed, Elsevier Science Direct, Excerpta Medica Database (Embase) and Chinese Biomedical Literature Database (CBM) before May 2013. The association between the XRCC3 Thr241Met polymorphism and gliomas risk was conducted by odds ratios (ORs) and 95% confidence intervals (95% CIs). A total of nine case-control studies including 3,533 cases and 4,696 controls were eventually collected. Overall, we found that XRCC3 Thr241Met polymorphism was significantly associated with the risk of gliomas (T vs. C: OR=1.10, 95%CI=1.01-1.20, P=0.034; TT vs. CC: OR=1.30, 95%CI=1.03-1.65, P=0.027; TT vs.
  OR=1.29, 95%CI=1.01-1.64, P=0.039). In the subgroup analysis based on ethnicity, the significant association was found in Asian under four models (T vs. C: OR=1.17, 95%CI=1.07-1.28, P=0.00; TT vs. CC: OR=1.79, 95%CI=1.36- 2.36, P=0.00; TT vs.
  OR=1.75, 95%CI=1.32-2.32, P=0.00; TT/TC vs. CC: OR=1.11,95% CI=1.02-1.20). This meta-analysis suggested that the XRCC3 Thr241Met polymorphism is a risk factor for gliomas, especially for Asians. Considering the limited sample size and ethnicities included in the meta-analysis, further large scale and well-designed studies are needed to confirm our results.
authors.affiliation: Department of Clinical Laboratory, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China. lis8858@126.com
authors.forename: Hong-Jie
authors.initials: HJ
authors.lastname: Liang
authors.forename: Yu-Lan
authors.initials: YL
authors.lastname: Yan
authors.forename: Zhi-Ming
authors.initials: ZM
authors.lastname: Liu
authors.forename: Xu
authors.initials: X
authors.lastname: Chen
authors.forename: Qi-Liu
authors.initials: QL
authors.lastname: Peng
authors.forename: Jian
authors.initials: J
authors.lastname: Wang
authors.forename: Cui-Ju
authors.initials: CJ
authors.lastname: Mo
authors.forename: Jing-Zhe
authors.initials: JZ
authors.lastname: Sui
authors.forename: Jun-Rong
authors.initials: JR
authors.lastname: Wu
authors.forename: Li-Min
authors.initials: LM
authors.lastname: Zhai
authors.forename: Shi
authors.initials: S
authors.lastname: Yang
authors.forename: Tai-Jie
authors.initials: TJ
authors.lastname: Li
authors.forename: Ruo-Lin
authors.initials: RL
authors.lastname: Li
authors.forename: Shan
authors.initials: S
authors.lastname: Li
authors.forename: Xue
authors.initials: X
authors.lastname: Qin
mesh_terms: D001932:Brain Neoplasms / Q000209:etiology*; D016022:Case-Control Studies; D004268:DNA-Binding Proteins / Q000235:genetics*; D020022:Genetic Predisposition to Disease; D005910:Glioma / Q000209:etiology*; D006801:Humans; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D011379:Prognosis; D012307:Risk Factors
chemical_list: D004268:DNA-Binding Proteins; C110901:X-ray repair cross complementing protein 3